Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Publication year range
1.
Ideggyogy Sz ; 59(5-6): 179-82, 2006 May 20.
Article in Hungarian | MEDLINE | ID: mdl-16786712

ABSTRACT

OBJECTIVE: To evaluate the efficacy and tolerability of levetiracetam in children with drug resistant epilepsy from a retrospective study. METHODS: We report the result of a study of 85 pediatric patients (mean 10.5 years, range: 1-24) with refractory generalized and focal epilepsy, who received levetiracetam as add-on treatment. The average duration of epilepsy was eight years, and the patient were treated with mean of 6.0 antiepileptic drugs before levetiracetam was introduced. RESULTS: Ten patients (12%) became seizure-free, three (3%) responded with seizure reduction of more than 90%, 32 (38%) responded with seizure reduction of more than 50% following introduction of levetiracetam. No response to levetiracetam was reported in 34% (n: 29). Positive psychotropic effect was observed in 26 patient (30%). Mild to moderate side effects were reported in 11 patients (13%), consisting most frequently general behavioral changes, aggression, sleep disturbances, but they ceased after decreasing the dose of levetiracetam. Mental retardation was associated with poor response and associated with more side effects. CONCLUSION: Levetiracetam is a well tolerated new antiepileptic drug that may effectively improve seizures control as an add-on drug in resistant epilepsy in childhood with good tolerability.


Subject(s)
Anticonvulsants/therapeutic use , Epilepsy/drug therapy , Piracetam/analogs & derivatives , Adolescent , Adult , Age of Onset , Anticonvulsants/administration & dosage , Anticonvulsants/adverse effects , Child , Child, Preschool , Epilepsy/complications , Female , Humans , Infant , Intellectual Disability/complications , Levetiracetam , Male , Piracetam/administration & dosage , Piracetam/adverse effects , Piracetam/therapeutic use , Retrospective Studies , Treatment Outcome
2.
Ideggyogy Sz ; 58(1-2): 21-31, 2005 Jan 20.
Article in English | MEDLINE | ID: mdl-15884395

ABSTRACT

In this work the authors provide evidences for a unifying concept of the syndromes of benign focal childhood epilepsies, Landau-Kleffner syndrome, and electrical status epilepticus in sleep treating them as a spectrum of disorders with a common transient, age dependent, non lesional, genetically based epileptogenic abnormality, the nature of which is still not known. The electro-clinical features of these syndromes are congruent with the different degree involvement of the perisylvian cognitive network and with the involvement of the thalamo-cortical associative system of variable degree. These epilepsies are characterized by the abundance of regional epileptiform discharges in sharp contrast with the rare and in several cases lacking seizures. The nature and severity of interictal cognitive symptoms are closely related to localization within the network and amount of epileptic interictal discharges. Spike-wave discharges are attributed to an alternation of overexcitation (spikes) and overinhibition (waves). The recurrent overinhibition represented by the wave of the discharges may interfere with the continuous depolarization of the cells of a large population of neurons, which is a requirement of the overt seizures. The overinhibition also interfere with cognitive processes which are correlated with the continuous presence of the fast (gamma) activity, binding the required cortical areas. Hence the recurrent inhibition works against the existence of the binding fast frequency activity. This is the assumed reason for the co-existence of the relative lack of overt seizures and in the same time for the frequently observed epileptogenic cognitive deficit symptoms ("cognitive epilepsies"). The time course of these syndromes overlaps with important developmental milestones. The frequent epileptic discharges alters the evolution of the perisylvian network developing late after early childhood and is very vulnerable for any interference in this imprinting time for speech and other cognitive functions. This spectrum of disorders represents a type of age linked, mild to severe 'epileptic encephalopathy' limited to the perisylvian network, where the cognitive impairment is caused by epileptic discharges interfering with cognitive development.


Subject(s)
Cognition Disorders/etiology , Epilepsies, Partial , Epilepsy, Rolandic , Landau-Kleffner Syndrome , Sleep , Status Epilepticus , Cognition , Cognition Disorders/physiopathology , Electroencephalography , Epilepsies, Partial/complications , Epilepsies, Partial/physiopathology , Epilepsy, Rolandic/complications , Epilepsy, Rolandic/physiopathology , Humans , Landau-Kleffner Syndrome/complications , Landau-Kleffner Syndrome/physiopathology , Neuropsychological Tests , Status Epilepticus/complications , Status Epilepticus/physiopathology
3.
Orv Hetil ; 145(51): 2583-7, 2004 Dec 19.
Article in Hungarian | MEDLINE | ID: mdl-15715292

ABSTRACT

The role of melatonin in human physiology until the second part of XX. century was unknown. The effects of melatonin have been studied in many physiological or pathological states of humans. There is now evidence that melatonin may have a role in many different actions, such as sleep promotion, control of biologic rhythm, mood, reproduction, tumor growth and aging. The authors report about the administration of melatonin for two pediatric epileptic patients, who suffer from intractable epilepsy. Their epilepsy was early onset, and different anticonvulsive treatments have been administered for them for many years, ineffectively. However, in response to 3 mg melatonin co-medication (administered in the evenings 30 min before patient's habitual bedtime) suppression of seizure activity has been shown on the EEG record of both children, and the number of their convulsions reduced clinically too. 3 month later the melatonin co-medication was stopped. The seizures appeared again.


Subject(s)
Anticonvulsants/therapeutic use , Epilepsy/drug therapy , Melatonin/therapeutic use , Age of Onset , Child, Preschool , Drug Resistance , Drug Therapy, Combination , Electroencephalography/drug effects , Epilepsy/physiopathology , Female , Humans , Male , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL